l e t t e r s
Cancer cells experience higher oxidative stress from reactive oxygen species (ROS) than do non-malignant cells because of genetic alterations and abnormal growth; as a result, maintenance of the antioxidant glutathione (GSH) is essential for their survival and proliferation [1] [2] [3] . Under conditions of elevated ROS, endogenous l-cysteine (l-Cys) production is insufficient for GSH synthesis. This necessitates uptake of l-Cys that is predominantly in its disulfide form, l-cystine (CSSC), via the xCT(−) transporter. We show that administration of an engineered and pharmacologically optimized human cyst(e)inase enzyme mediates sustained depletion of the extracellular l-Cys and CSSC pool in mice and non-human primates. Treatment with this enzyme selectively causes cell cycle arrest and death in cancer cells due to depletion of intracellular GSH and ensuing elevated ROS; yet this treatment results in no apparent toxicities in mice even after months of continuous treatment. Cyst(e)inase suppressed the growth of prostate carcinoma allografts, reduced tumor growth in both prostate and breast cancer xenografts and doubled the median survival time of TCL1-Tg:p53 −/− mice, which develop disease resembling human chronic lymphocytic leukemia. It was observed that enzyme-mediated depletion of the serum l-Cys and CSSC pool suppresses the growth of multiple tumors, yet is very well tolerated for prolonged periods, suggesting that cyst(e)inase represents a safe and effective therapeutic modality for inactivating antioxidant cellular responses in a wide range of malignancies 4, 5 .
As a precursor for the biosynthesis of GSH, l-Cys is essential for maintaining the intracellular thiol redox potential. l-Cys is produced via the transsulfuration pathway enzymes cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CGL), which are widely expressed in numerous tissues in humans (Fig. 1a) [6] [7] [8] [9] . In contrast, some tumors have a markedly lower expression of transsulfuration enzymes, which is typically a result of transcriptional silencing 10, 11 . Furthermore, even in cancers with an intact transsulfuration pathway, endogenous l-Cys synthesis is often insufficient, owing to markedly increased ROS levels arising from rapid proliferation, metabolic dysregulation and oncogene expression. Consequently, the import of extracellular l-Cys becomes necessary to meet cellular GSH requirements [12] [13] [14] [15] [16] . The main route for extracellular acquisition of l-Cys is the transport of its disulfide form, CSSC, through the xCT(−) CSSC/l-glutamate (l-Glu) antiporter (SLC7A11) (Fig. 1a) . Because there is a high demand for CSSC in numerous malignancies, xCT(−) represents a key therapeutic target, with small-molecule inhibitors of the xCT(−) antiporter displaying anti-tumor effects [12] [13] [14] [15] . l-Cys is a non-essential amino acid in animals; therefore, eliminating l-Cys and CSSC uptake should selectively impact tumors that display increased ROS production and thus exhibit a higher demand for antioxidants, without causing an adverse effect on normal physiology. However, inhibition of xCT(−) alone is insufficient because free l-Cys is still imported via other transporters (for example, the system ASC transporters ASCT1 and ASCT2). A superior approach to small-molecule inhibition of multiple transporters exists: elimination of the extracellular pool of l-Cys and CSSC through the action of an enzyme that converts these amino acids into non-toxic and readily metabolizable products.
The pyridoxal phosphate (PLP)-dependent enzyme CGL (EC 4.4.1.1) catalyzes the last step in de novo l-Cys synthesis: the conversion of l-cystathionine (l-Cysta) into α-ketobutyrate, l-Cys and NH 4 + . CGL can also accept two other substrates in addition to l-Cysta. One of these is l-Cys, which produces pyruvate, NH 4 + and H 2 S; the other is CSSC, which produces pyruvate, NH 4 + and thiocysteine. Although CGL can degrade both CSSC and l-Cys, its kinetic rates are too slow to be relevant for clinical applications given that dosing at >2 g per kg body weight would be required to achieve substantial reduction of serum l-Cys and CSSC levels in mice. Structural analyses l e t t e r s of CGL (PDB 3COG) suggested that amino acid substitutions in place of active site residues Glu59 and Glu339, which are important for l-Cysta coordination, could enhance l-Cys and CSSC degrading activity. Combinatorial saturation mutagenesis of these residues coupled with a high-throughput assay for pyruvate production led to the isolation of CGL-E59T-E339V. It exhibits 25-and 50-fold higher k cat /K M values than wild-type CGL for l-Cys and CSSC, respectively (Fig. 1b) . Solving the X-ray structure of CGL-E59T-E339V in the presence of 1 mM l-Cys at 2.7Å revealed a structure that is essentially identical to that of wild-type CGL. The two differ in the existence of minor perturbations at CGL-E59T-E339V's mutation sites (0.66-Å root mean square deviation from PDB 2NMP), as well as its substrate complexes within the four active sites of the tetramer (Supplementary Table 1 ). In two of the aforementioned active sites, the amine of l-Cys forms a geminal diamine with the PLP cofactor and the ε-amine of Lys212. This geminal diamine is a reaction intermediate created immediately before the l-Cys-external aldimine complex is formed; this complex is further stabilized by a salt bridge to the l-Cys α-carboxyl group and the guanidinium moiety of Arg375 (Fig. 1c) . Collectively, the structural and kinetic data indicate that the E339V substitution increases the hydrophobicity of the active site to enhance l-Cys binding 17, 18 , whereas the removal of the Glu339 and Glu59 carboxyl groups better accommodates CSSC binding; this conclusion is further supported by molecular dynamic modeling (Supplementary Fig. 1 ).
To prevent renal clearance and thus impart long circulation persistence, CGL-E59T-E339V was conjugated to methoxy PEG succinimidyl carboxymethyl ester, MW 5,000 Da (Supplementary Fig. 2 ) (conjugated protein henceforth referred to as cyst(e)inase). Singledose administration of cyst(e)inase at 8 mg per kg body weight to two cynomolgus monkeys resulted in a marked reduction in total serum l-Cys content (free + liberated protein-bound l-Cys and CSSC) for 28 h (Fig. 1d) with no observed toxicities (based on hematology, blood chemistry and animal observations; see Supplementary Data Set 1), indicating that cyst(e)inase is able to modulate blood l-Cys and CSSC levels in primates.
Increased ROS production has been widely noted in human prostate carcinomas (PCa), with high levels of ROS correlating with an aggressive phenotype [19] [20] [21] . We therefore evaluated the effect of cyst(e)inase on two human PCa cell lines, PC3 and DU145, as well as a murine PCa cell line, HMVP2 22 , derived from the ventral prostate of HiMyc-transgenic mice 23 . The HMVP2 murine PCa cell line constitutes a relevant model to human disease as it possesses characteristics of cancer stem cells, expresses stem cell markers (such as LIN neg , Sca-1 high , CD49f high , CK14 and CD29) and produces spheroids 22 . Cyst(e)inase potently inhibited survival of HMVP2 cells, with an IC 50 of 23 ± 4 nM (Fig. 2a) . A dose-dependent significant increase in ROS (P < 0.001) was evident by 4 h after enzyme addition, with a concomitant significant decrease in cellular GSH levels (P < 0.001) by 24 h (Fig. 2b,c) . Consistent with the well-established effects of ROS accumulation and amino acid restriction in eliciting autophagic responses [24] [25] [26] , cyst(e)inase treatment increased AMPK phosphorylation (pAMPK Thr172 ) (Fig. 2d) , reduced phosphorylated mTOR (pmTOR Ser2448 ) and increased autophagic responses as manifested by changes in the protein phosphorylation levels of mTORC1 and further downstream substrates such as p70S6K, ribosomal protein S6 and ULK1, as well as formation of the autophagosome marker LC3 II (Fig. 2e,f) . Similarly, cyst(e)inase treatment of the human cell line PC3 resulted in dose-dependent cell killing, a 4-to 6-fold increase of pAMPK Thr172 and increased autophagic responses ( Supplementary  Fig. 3a-d) . AMPK and p70S6K can directly affect cell cycle progression 27, 28 , and we observed a significant dose-dependent arrest in G 0 /G 1 with a corresponding significant decrease of cells in S-phase and a non-significant but slight increase in G 2 /M populations (Fig. 2g) . The G 0 /G 1 arrest was accompanied with a dose-dependent increase in protein levels of the cyclin-dependent kinase inhibitor p27 (>7-fold, Fig. 2h ), whose accumulation can be stabilized by pAMPK 27 . 
We also detected decreased protein levels of c-Myc, the cyclin-dependent kinases CDK2 and CDK4, phosphorylated retinoblastoma protein (pRB Ser807/811 ), E2F4 and cyclins A, D1 and E1 (Fig. 2h,i) . Conversely, and consistent with a ROS driven mechanism, we found that treating cells with the ROS scavenger and l-Cys donor N-acetyl-l-cysteine partially restored cell survival ( Fig. 2j and Supplementary Fig. 3e ).
To assess the antitumor activity of cyst(e)inase in vivo in murine models, we first established an appropriate dosing schedule by measuring the pharmacokinetics of cyst(e)inase and its pharmacodynamics effect on thiol-containing metabolites in serum in mice. Following single-dose intraperitoneal (i.p.) (50 mg/kg) administration of cyst(e)inase in non-tumor-bearing FVB/N mice (a strain inbred for the Fv1b allele), we observed a clearance half-life of 25 ± 2 h, with the data fitting well in regards to an extravascular clearance model 29 ( Fig. 3a) . Similar to the observations in cynomolgus monkeys, no weight loss, adverse effects nor organ abnormalities upon necropsy were observed in the mice (data not shown). Time-course analysis of serum metabolomic profiles revealed near complete elimination of serum CSSC for 4 d, before levels recovered to pre-administration concentrations at day 6 ( Fig. 3b) . Free l-Cys levels were reduced by over four-fold for 2 d before gradually recovering (Fig. 3b) . The impact of cyst(e)inase on the concentration of other sulfur containing metabolites was consistent with their respective steadystate serum concentrations, enzyme kinetics and the consequences of depleting extracellular l-Cys and CSSC ( Supplementary Fig. 4) . From a clinical translation standpoint, this treatment corresponds to realistic clinical doses (based on allometric scaling, a 50 mg/kg dose in mice corresponds to a 6.5 mg/kg dose in humans 30 ). Immunoblots were performed at least three times with β-actin controls for each experiment. Numbers above blots indicate band intensities relative to untreated conditions. Images have been cropped for presentation; uncropped images are shown in Supplementary  Figure 14 . (g) Cell-cycle phase distribution was analyzed by Guava-based flow cytometry 24 h after treatment (n = 5 independent experiments). (j) DU145 PCa cells were treated with indicated concentrations of cyst(e)inase and/or N-acetyl-l-cysteine (NAC) for 48 h, and cell viability was assessed by crystal violet assay (n = 5 cell culture replicates at each dose). For a-c,g,j, data are expressed as mean ± s.e.m.; *P < 0.05; ***P < 0.001; ****P < 0.0001; one-way ANOVA followed by Tukey's multiple-comparison test (a-c,g) or Bonferroni's multiple-comparison test (j).
We then treated (via i.p. injection) syngeneic male FVB/N mice bearing palpable HMVP2 tumors with either 50 or 100 mg/kg cyst(e)inase and either PBS or 100 mg/kg heat-inactivated cyst(e)inase as controls every 4 d for 4 weeks. Tumors did not increase in size in either cyst(e)inase-treated group, whereas mice injected with heat-inactivated enzyme (a control for the presence of residual impurities and endotoxin in active protein) showed identical tumor growth to the PBS-treated group (Fig. 3c) . Throughout the treatment period, neither weight loss nor inappetence was observed (Fig. 3d) . Additionally, no adverse effects were detected by examination of tissues upon necropsy (data not shown). ; heat-inactivated cyst(e)inase, n = 6; 50 mg/kg cyst(e)inase, n = 7; 100 mg/kg cyst(e)inase, n = 7. (e,f) Quantification of tumor volume in male nude mice bearing xenograft tumors of (e) DU145 PCa cells (e; n = 8 per group) and (f) PC3 PCa cells (f; n = 7 per group) following treatment with active cyst(e)inase or controls. For all studies, dosing was terminated when control tumors reached an endpoint. Throughout, data are expressed as mean ± s.e.m. For b-f, *P < 0.05; **P < 0.001; *** P < 0.0001; two-sided Student's t-test (b); repeated-measures two-way ANOVA followed by Bonferroni's multiple-comparison test (c,d: body weight, e,f) or one-way ANOVA followed by Bonferroni's multiple-comparison test (d: food consumption).
Similarly, cyst(e)inase treatment in male nude mice under the same dosing schedule significantly blocked growth of both DU145 (P < 0.0001 at 100 mg/kg, Fig. 3e ) and PC3 xenograft tumors (P < 0.0001 at 50 and 100 mg/kg, Fig. 3f ). Once again, no weight loss or inappetance was observed, nor were changes in blood cell counts or blood chemistry (Supplementary Figs. 5 and 6) . Macroscopically (at the time of euthanization), the liver and other major organs in treated mice looked similar to those in control mice, with no obvious signs of toxicity (data not shown). We also microscopically examined H&E-stained sections of liver tissue from both control and treated mice. The liver of cyst(e)inase-treated mice was normal in histologic appearance; it maintained normal hepatic architecture with no obvious signs of cellular toxicity (data not shown). Because ocular tissues are known to have a high demand for CSSC 31, 32 , we also performed histological examinations of ocular sections and found no evidence of changes in tissue ultrastructure as compared to control groups, further underscoring that cyst(e)inase treatment is well tolerated (data not shown). In addition to prostate carcinomas, cyst(e)inase may be beneficial for the treatment of a wide range of cancers. Notably, human breast carcinomas upregulate xCT(−) 12, 33 ; therefore, this type of cancer may be one that could benefit from cyst(e)inase treatment. Accordingly, cyst(e)inase administration significantly abrogated the growth of MDA-MB-361 breast cancer xenografts orthotopically implanted into female NOD SCID mice (P < 0.0001 at 50 and 100 mg/kg; Supplementary Fig. 7 ), which suggests a common tumoral dependence on l-Cys and CSSC.
To further confirm that cyst(e)inase impacts tumors by affecting cellular thiol antioxidant pathways, we investigated the effect of cyst(e)inase in combination with well-established drug candidates that target either the GSH or thioredoxin (TXN)-thioredoxin reductase (TXNR) pathways. For these studies we used two drug candidates-buthionine sulfoximine (BSO), which inhibits GSH synthesis, and the natural product curcumin (the active component of turmeric), which irreversibly inhibits TXNR 34 and is being evaluated in numerous clinical trials as a therapy for various neoplasias [35] [36] [37] . We compared the effects of cyst(e)inase with those of either BSO or curcumin both alone and in combination on DU145 PCa cell viability using an MTT assay. Cyst(e)inase was far more cytotoxic than BSO alone, but the combination showed a synergistic effect (Supplementary Fig. 8a) . Similarly, we observed that curcumin synergized with cyst(e)inase in DU145 cells and in the PCa cell line 22Rv1, which is very aggressive and castration resistant (Supplementary Fig. 8b,c) . Cyst(e)inase treatment in combination with either BSO or curcumin led to a significant increase in cellular ROS levels (P < 0.01 as compared to l e t t e r s treatment with individual agents) (Supplementary Fig. 8d-f) . In vivo, and consistent with the in vitro results, only slight tumor inhibition was observed in male nude mice implanted with 22Rv1 cells when treated with moderate cyst(e)inase (25 mg/kg) or curcumin (1% (w/w) in diet) doses, whereas co-administration of cyst(e)inase and curcumin significantly enhanced tumor growth inhibition ( Supplementary  Fig. 8g) . Notably, treatment with a higher dose of cyst(e)inase (100 mg/kg) as a single agent displayed analogous efficacy to the combination treatment (Supplementary Fig. 8g ), suggesting that cyst(e)inase treatment simultaneously effects both the GSH and TXN antioxidant pathways. Recently Huang et al. reported that primary leukemia cells isolated from chronic lymphocytic leukemia (CLL) patients rely on cysteine uptake for GSH production, but have low xCT(−) expression 16 . Consequently, CLL cell viability is dependent on stromal protection, where surrounding bone marrow stromal cells (which highly express xCT(−)) uptake CSSC for conversion to l-Cys that is then released into the microenvironment for uptake by CLL cells (via system ASC transporters). The reliance of CLL cells on stromal protection is further shown in vitro, where a high level of spontaneous apoptosis is observed in CLL cells cultured alone; however, co-culture with stromal cells significantly enhances cell viability 16 . Accordingly, we compared the effect of cyst(e)inase to that of the CLL standard of care drug fludarabine (or their combination) in mouse leukemic cells isolated from TCL1-Tg:p53 −/− mice, a model with a TCL1 transgenic and p53 (Tp53) deletion genotype that exhibits highly aggressive disease progression with 100% penetrance and a drug-resistant phenotype that mimics human CLL with a chromosomal 17p deletion (which is associated with poor clinical outcomes) 38 . TCL1-Tg:p53 −/− mice develop splenomegaly, with IgM + CD5 + B leukemic cells representing 80-90% of total cells in the spleen. TCL1-Tg:p53 −/− splenocytes co-cultured with murine stromal Kusa-H cells (to mimic the protective CLL microenvironment) were minimally affected by fludarabine, yet were potently killed by cyst(e)inase (Fig. 4a and Supplementary Fig. 9) .
We then performed a long-term survival experiment in TCL1-Tg:p53 −/− mice treated with either fludarabine, cyst(e)inase or their combination starting at ~2 months of age, at which point the mice begin to develop disease. As shown in Figure 4b , untreated TCL1-Tg:p53 −/− mice (n = 47) displayed a median survival time of 3.5 months whereas fludarabine treatment improved the median survival time to 5.3 months (P < 0.001); consistent with the in vitro results, cyst(e)inase displayed superior efficacy to the standard of care drug fludarabine, exhibiting a significantly longer median survival time of 7 months (P < 0.0001). A combination of fludarabine and cyst(e)inase showed a slight but not statistically significant improvement in median survival (P = 0.092, 7.4 months versus 7 months, Fig. 4b ) relative to cyst(e)inase alone. It is noteworthy that the longest-surviving mice in this study were treated with cyst(e)inase twice a week for over 5 months without any signs of toxicity or weight loss ( Supplementary  Fig. 10 ). Finally, we tested the efficacy of cyst(e)inase, fludarabine or their combination ex vivo against primary leukemia cells isolated from CLL patients with or without 17p deletions, and either cultured alone or co-cultured with the human bone marrow stromal cell line NKTert (as previously stated, co-culture with stromal cells mimics the protective CLL microenvironment). Cyst(e)inase treatment (alone or in combination with fludarabine) was highly efficacious in killing both 17p wild type (wt) and 17p − CLL cells as assessed by flow cytometry following double staining of cells with annexin-V and PI (n = 6 CLL patient samples for each phenotype, Fig. 4c,d and Supplementary  Fig. 11) , even in the presence of stromal cell protection. In contrast, fludarabine treatment alone only moderately impacted 17p wt CLL cells and was far less efficacious against 17p − CLL samples, consistent with the known chemotherapeutic resistance arising from 17p deletions 38 . Both patient-derived CLL cells and mouse TCL1-Tg:p53 −/− splenocytes showed a marked reduction in GSH levels following treatment with 0.1 µM cyst(e)inase (Fig. 4e) and a concomitant increase in superoxide levels (Supplementary Fig. 12) . Treatment with 0.1 µM cyst(e)inase had a very slight effect (12% reduction) on the viability of non-malignant B lymphocytes from healthy donors co-cultured with NKTert stromal cells, and even higher concentrations only moderately effected viability (21% and 30% reduction with 0.2 µM or 0.5 µM, respectively, Fig. 4f and Supplementary Fig. 13 ). In conclusion, cyst(e)inase was highly effective in treating CLL with 17p deletions, which are more aggressive and resistant to standard of care drugs such as fludarabine 38 . Based on these results, we expect that other hematological malignancies with intrinsically high ROS will be affected by l-Cys and CSSC depletion.
There are several reasons that tumors critically depend on the uptake of extracellular l-Cys and CSSC for the production of antioxidants. First, inflammation in the tumor microenvironment and the accompanying exogenous ROS stress greatly increase the cellular demand for antioxidants 39 . Second, activation of oncogenes such as c-Myc, Ras or Bcr-abl, loss of functional p53 and metabolic imbalances cause significant increases in internal ROS stress relative to non-malignant tissues 1, 40 . Third, many tumors are deficient in expression of transsulfuration pathway enzymes 41 , and significant downregulation of CBS correlates with tumor progression and shorter overall survival 11 . Fourth, there is growing evidence that besides the GSH antioxidant pathway, the l-Cys pool, in conjunction with the TXN enzymes, represents an ancillary redox buffer system 3, 42, 43 that can compensate for GSH deficiencies.
We show that cyst(e)inase treatment increases ROS and reduces GSH levels in PCa and CLL models (Figs. 2b,c and 4e and Supplementary  Fig. 12 ). In PCa cell lines, the ensuing increase in ROS mediates the activation of AMPK and the induction of autophagy, consistent with previous observations of the effects of high ROS in tumors [24] [25] [26] (Fig. 2d-f and Supplementary Fig. 3b-d) . In contrast, CLL cells rapidly undergo apoptosis following cyst(e)inase treatment ( Supplementary Figs. 9  and 11 ). CLL cells have intrinsically higher basal ROS and lower GSH levels 44 , suggesting that they are highly sensitive to additional ROSmediated damage caused by depletion of l-Cys and CSSC. Likewise, rapid apoptosis is observed in CLL cells treated with the GSH-depleting drug β-phenylethyl isothiocyanate. This leads to degradation of the anti-apoptotic myeloid cell leukemia 1 protein 44, 45 , which suggests that there is insufficient time for autophagy to occur in CLL cells.
Collectively, our results-in conjunction with earlier studiessupport the likelihood that cysteine is a critical metabolite for both the GSH and TXN antioxidant pathways. As cyst(e)inase simultaneously affects both the GSH and TXN pathways, it is not surprising that it synergizes with other ROS-inducing drugs targeting these pathways such as BSO or curcumin 46, 47 (Supplementary Fig. 8 ). Synergism with curcumin is especially noteworthy because it has been shown to irreversibly inactivate TXNR by covalent modification of two active site residues, in turn inducing NADPH oxidase activity, thus converting the enzyme from an antioxidant to a pro-oxidant 34 . Curcumin is currently under evaluation for the treatment of various neoplasias in eight or more open clinical trials [35] [36] [37] . As many other chemotherapeutic agents are also known to oxidatively stress cancer cells, we expect that cyst(e)inase will be highly efficacious in combination therapies with other ROS-inducing drugs such as bortezomib
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Protein expression and purification. E.coli-BL21(DE3) cells harboring plasmids of CGL variants were grown in Terrific Broth (TB) media containing 50 µg/mL kanamycin at 37 °C to an OD 600 of ~0.5 at which time Isopropyl β-D-1-thiogalactopyranoside (IPTG; Fisher Scientific) was added to a final concentration of 1 mM. After an additional ~16 h of incubation at 25 °C, cells were collected by centrifugation and re-suspended in immobilized metal affinity chromatography (IMAC) buffer (10 mM NaPO 4 /30 mM imidazole/300 mM NaCl, pH 8) additionally containing pyridoxal-5′-phosphate (PLP; 0.5 mM; Sigma), phenylmethanesulfonyl fluoride (PMSF; 10 µM; Sigma) and DNase (1 µg/mL; Sigma). The re-suspended cells were then lysed by a French pressure cell, and the lysates were centrifuged at 24,000 × g for 1 h at 4 °C. The resulting supernatant was applied to a nickel IMAC column, washed with 10-20 column volumes of IMAC buffer (containing 0.5 mM PLP), and eluted with 5 column volumes of IMAC elution buffer (50 mM NaPO 4 /250 mM imidazole/ 300 mM NaCl, pH 8). All chromatography was performed at 4 °C. Eluted enzyme was then incubated with 10 mM PLP for a minimum of 1 h at 4 °C. Using a 10,000 MWCO centrifugal filter device (Amicon), protein was then buffer exchanged into a solution comprised of phosphate buffered saline (PBS), 10% glycerol, pH 7.4. After sufficient buffer exchange, aliquots of purified enzyme were then flash frozen in liquid nitrogen and stored at -80 °C. To determine protein concentrations, extinction coefficients were calculated based on amino acid sequence (ε 280 = 29,870 M −1 cm −1 for CGL). All protein concentrations were determined from the absorption at 280 nm in 6 M guanidinium hydrochloride, 20 mM phosphate buffer, pH 6.5. Purity of the protein was assessed by SDS-PAGE.
Kinetic assays. Kinetic analyses were performed by measuring pyruvate production from l-Cys or CSSC by reaction with 3-methyl-2-benzothiazolone hydrazone hydrochloride (MBTH; Sigma) to generate a chromophore with a λ max of ~320 nm. Eppendorf tubes (1.5 mL) containing 220 µL of substrate (at various concentrations) or blanks in a 100 mM sodium phosphate buffer, 1 mM EDTA (pH 7.3), and 10 µM PLP were equilibrated in a 37 °C heat block for a minimum of five minutes. Reactions were started by adding 20.3 µL of enzyme solution and quenched with 26.7 µL of 50% trichloroacetic acid after a set length of time. All reactions were carried out in triplicate. Reactions and blanks were then mixed with 733 µL of MBTH solution (2.2 mL: 1.6 mL of 1 M sodium acetate buffer pH 5.0 and 0.6 mL of 0.1% MBTH in same) and incubated at 50 °C for 40 min. After cooling, the samples were transferred to cuvettes and the A 320 nm was determined. The assay was shown to be linear between 0-250 µM pyruvate with a lower detection limit of ~10 µM. When CSSC was the substrate, additional kinetic analyses were carried out in a continuous assay by detection of free thiol with 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) using 96-well plates and a microtiter plate reader (Biotek Instruments, Winooski, VT) set at 412 nm.
Diffraction data collection and structure determination. Full crystallization conditions can be found in the Supplementary Methods. X-ray diffraction data was collected at the Advanced Light source beamline BL 5.0.3 (Berkeley, CA) and processed using the HKL 2000 49 software suite. A significant off-origin peak in the Patterson map (23% of the height of the origin) was observed using the FFT program in the CCP4 suite, implicating the existence of pseudotranslational symmetry (tNCS). The pseudo-translational vector was refined to be (0.5, 0.38, 0.5) using Phaser (CCP4 suite) 50 . Correction of the intensity of this peak allowed for solving the crystal by molecular replacement (MR) with wild-type CGL (PDB 2NMP) as the search model using Phaser 50 . Refinement of the initial model was accomplished through iterative model building in COOT 51 and models were refined using Phenix refine with 5% of the diffraction set as a test for R free cross-validation. Final values of R work and R free were found to be 19% and 23%, respectively. The evaluated CGL-E59T-E339V structure was analyzed using MolProbity, and it gave a MolProbity score of 3.18 (73rd percentile) and an all atom clash score of 21.03 (91st percentile). Data collection and refinement statistics are summarized in Supplementary Table 1. Molecular figures were generated using PyMOL 52 . The engineered human cystathionine gamma lyase (E59T, E339V) structure was deposited into the Worldwide Protein Data Bank with the PDB code of 5EIG.
Cell culture. Human prostate cancer (PCa) cell lines LNCaP, DU145 PC3, and 22Rv1 were purchased from the American type culture collection (ATCC; Manassas, VA). Cells were cultured in RPMI-1640 medium (Life Technologies) supplemented with FBS (FBS; 10%; Life Technologies). Cell lines were authenticated by genetic biomarkers and mycoplasma tests were performed by PCR amplification (Applied Biological Materials Inc.) and 4,6-diamidino-2-phenylindole (DAPI) staining. The murine prostate tumor cell line, HMVP2, was derived from the ventral prostate of HiMyc transgenic mice 23 aged one year and cultured in RPMI-1640 medium containing 10% FBS 22 . The human breast cancer cell line MDA-MB-361 (ATCC) was cultured in Dulbecco's modified Eagle medium (DMEM; Lonza) supplemented with 10% FBS and gentamicin (50 µg/mL, Lonza). All cells were cultured at 37 °C in 95% air and 5% CO 2 .
Isolation of CLL cells and cytotoxicity assays. Primary leukemia cells were isolated from the peripheral blood samples of CLL patients diagnosed according to the NCI criteria 53 . Proper informed consents under a research protocol approved by the Institutional Review Board (IRB) of MD Anderson Cancer Center were obtained from all patients before the collection of blood samples.
